Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While GHRP-2 is used in research to induce robust GH pulses and study anabolic and metabolic effects; clinically developed as pralmorelin for GH deficiency diagnostics6272, Ipamorelin is investigated for producing moderate, physiologic-like GH pulses useful for studying anabolic, body-composition, and recovery effects with a relatively clean endocrine side-effect profile compared with earlier GHRPs16.
While GHRP-2 works as a second-generation hexapeptide growth hormone–releasing peptide that mimics ghrelin by agonizing GHSR-1a, strongly stimulating pulsatile GH release and modestly raising prolactin, ACTH, and cortisol62723096, Ipamorelin is a third-generation pentapeptide growth hormone secretagogue that selectively agonizes the ghrelin (GHSR-1a) receptor to trigger controlled, GH-specific pituitary release with minimal effects on cortisol or prolactin16269596.
GHRP-2
GHSR
Ipamorelin
GHSR
GHRP-2 and Ipamorelin sit closest together within the GHRP family, which gives them a broadly related biological identity. Both are most often discussed in Metabolic and endocrine and Musculoskeletal health, which gives the comparison a meaningful common setting even when the rest of their profiles are not identical. Mechanistically, both point toward Receptor agonist and converge on Ghrelin receptor, although the downstream emphasis is not identical. Both are synthetic in origin with GHRP-2 in Clinical phase 1 and Ipamorelin in Preclinical development. They are also usually discussed through the same administration routes, namely subcutaneous injection.